Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Results from the SENTRY Antimicrobial Surveillance Programme, 2017

J Glob Antimicrob Resist. 2019 Dec:19:56-63. doi: 10.1016/j.jgar.2019.02.017. Epub 2019 Feb 27.


Objectives: Omadacycline is an aminomethylcycline antibacterial (oral and intravenous once-daily formulation) that recently (October 2018) received United States Food and Drug Administration (FDA) approval for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and community-acquired bacterial pneumonia (CABP) against selected organism groups. This study tested omadacycline and comparators against 14 000 non-duplicate bacterial isolates that were prospectively collected during 2017 from medical centres in Europe (EUR; 7000 isolates) and the United States (USA; 7000 isolates).

Methods: Omadacycline was tested by broth microdilution following Clinical and Laboratory Standards Institute M07-A11 (2018) methods.

Results: A total of 98.7% ofStaphylococcus aureus isolates were susceptible to omadacycline (MIC50/90, 0.12/0.25mg/L; ABSSSI breakpoints) including 96.5% of methicillin-resistant Staphylococcus aureus (MRSA), 99.8% of methicillin-susceptible Staphylococcus aureus, and 93.9% of tetracycline-resistant strains. Omadacycline activity was similar for Streptococcus pneumoniae (MIC50/90 0.06/0.12mg/L; 98.6% susceptible [CABP breakpoints]), Streptococcus anginosus group (MIC50/90 0.06/0.06mg/L; 100.0% susceptible [ABSSSI breakpoints]), and Streptococcus pyogenes (MIC50/90 0.06/0.12mg/L; 97.7% susceptible [ABSSSI breakpoints]). Omadacycline demonstrated activity against Enterobacter cloacae species complex isolates (MIC50/90, 2/4mg/L; 91.2% susceptible [ABSSSI breakpoints]), Klebsiella pneumoniae (MIC50/90, 2/8mg/L; 87.5% susceptible [CABP and ABSSSI breakpoints]), and inhibited 99.1% of Escherichia coli (MIC50/90, 0.5/2mg/L) isolates at ≤ 4mg/L. Omadacycline was active against Haemophilus influenzae (MIC50/90, 0.5/1mg/L; 99.8% susceptible [CABP breakpoints]), including all β-lactamase positive isolates, and inhibited 100.0% of Moraxella catarrhalis isolates at ≤ 0.25mg/L.

Conclusions: The potent activity of omadacycline against Gram-positive and Gram-negative bacteria indicates that omadacycline merits further study in serious infections in which multidrug resistance and mixed Gram-positive and Gram-negative infections may be of concern.

Keywords: Multidrug resistance; Omadacycline; Staphylococcus aureus; Streptococcus pneumoniae; Surveillance.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Community-Acquired Infections / microbiology
  • Drug Resistance, Multiple, Bacterial / drug effects
  • Europe
  • Gram-Negative Bacteria / drug effects*
  • Gram-Positive Bacteria / drug effects*
  • Humans
  • Methicillin-Resistant Staphylococcus aureus / drug effects
  • Microbial Sensitivity Tests
  • Streptococcus pneumoniae / drug effects
  • Tetracyclines / pharmacology*
  • United States
  • United States Food and Drug Administration


  • Anti-Bacterial Agents
  • Tetracyclines
  • omadacycline